The financial result matched the standing expectation. Second-quarter net loss was $0.76 per share, essentially matching the published consensus of approximately $0.76 loss per share. There was no quarterly license revenue, so the headline loss—not revenue—was the meaningful earnings comparison. (Condensed Statements of Operations)
| Metric | Q2 2026 | Q2 2025 | Six months 2026 | Six months 2025 |
|---|---|---|---|---|
| License revenue | $0 | $0 | $20.0 million | $0 (Condensed Statements of Operations) |
| R&D expense | $34.9 million | $28.1 million | $69.1 million | $55.7 million (Condensed Statements of Operations) |
| G&A expense | $13.1 million | $8.4 million | $25.5 million | $16.2 million (Condensed Statements of Operations) |
| Net loss | $44.7 million | $33.7 million | $68.9 million | $66.5 million (Condensed Statements of Operations) |
| Net loss per share | $0.76 | $0.77 | $1.22 | $1.83 (Condensed Statements of Operations) |
| Cash, equivalents and marketable securities | $494.9 million | — | $494.9 million | — (Condensed Balance Sheet Data) |
The core clinical update is progress, not a new value inflection. Enrollment in the Phase 2 HORIZON trial of MZE829 remains on track, with updated data from three 10–15-patient cohorts still expected in late 2026 or early 2027. The planned pivotal trial remains targeted for the first half of 2027, subject to regulatory feedback. (Program Progress and Anticipated Milestones — MZE829)
MZE782 also delivered against the existing schedule rather than raising it. The PKU Phase 2 CIPheR trial has started and is enrolling, while the CKD Phase 2 trial remains planned for the first half of 2027; both timelines were described as consistent with prior guidance. (Program Progress and Anticipated Milestones — MZE782)
The balance sheet reduces near-term financing pressure, but this was largely known. Cash rose to $494.9 million from $360.0 million at year-end, helped by the approximately $150 million April stock and pre-funded-warrant offering; management continues to project funding into 2029. (Recent Corporate Highlights; Condensed Balance Sheet Data) Higher R&D and G&A spending shows the pipeline is becoming more expensive to advance, but the filing provides no new financing surprise or runway extension beyond the previously communicated outlook.
Net read: an in-line quarter with execution intact, but no fresh clinical catalyst. The filing confirms the expected trial cadence and financial capacity without providing new efficacy data, upgraded timelines, or guidance changes. That makes it confirmation of the existing thesis rather than a meaningful change versus what the market already appeared to expect.
Read the original 8-K on SEC EDGAR ↗